Agile 3+
Identification of advanced fibrosis in MASLD patients
Current MASH drug developments focus on patients with MASH at-risk of progression to cirrhosis or with compensated cirrhosis defined by Active Fibrotic MASH (MASH + NAS≥4 + F≥2).
Fast combines FibroScan® examination results (LSM by VCTE™ & CAP™) with an easily accessible blood biomarker (AST) to help identify patients with active fibrotic-MASH, at the point-of-care, reducing invasive and costly procedures.
Good to excellent performance in derivation cohort as well as in external validation cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia).
Several publications advocate the use of Fast.
Fast is an in vitro diagnostic medical device according to directive 98/79/EC.Fast calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of MASLD as being at risk for active fibrotic MASH (MASH+NAS≥4+F≥2). It was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Fast is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.
*MASLD/MASH is formerly knowed as NAFLD/NASH
To access the Fast User Guides, connect to myfibroscan.com:
Scores > Fast > Learn more
Identification of advanced fibrosis in MASLD patients
Identification of cirrhosis in patients with MASLD
Cloud-based solution to assist clinicians in providing comprehensive liver care.
The non-invasive gold standard solution for comprehensive management of liver health